Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 345138, 13 pages
http://dx.doi.org/10.1155/2015/345138
Review Article

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations

1Department of Pharmacy, University of Namur, Namur Thrombosis and Haemostasis Center (NTHC), Namur Research Institute of Life Sciences (NARILIS), 5000 Namur, Belgium
2Department of Haemostasis, University Hospital Frankfurt, 60596 Frankfurt am Main, Germany
3Department of Haematology, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Haemostasis Center (NTHC), Namur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium
4Haematology Laboratory, CHU Dinant-Godinne UCL Namur, Namur Thrombosis and Haemostasis Center (NTHC), Namur Research Institute of Life Sciences (NARILIS), 5530 Yvoir, Belgium

Received 30 May 2014; Accepted 10 November 2014

Academic Editor: Jack Ansell

Copyright © 2015 Jonathan Douxfils et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Bloemen, M. De Laat, B. De Laat, H. C. Hemker, and R. Al Dieri, “Will one size of anticoagulant dosage fit all?” Drug Development Research, vol. 74, no. 7, pp. 406–412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. H. ten Cate, “New oral anticoagulants: discussion on monitoring and adherence should start now!,” Thrombosis Journal, vol. 11, no. 1, article 8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. European Medicine Agency-Xarelto, “Summary of Product Characteristics,” 2013, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
  4. European Medicine Agency-Pradaxa, “Summary of Product Characteristics,” 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
  5. European Medicine Agency, Eliquis: Summary of Product Characteristics 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.
  6. Food and Drug Administration-Pradaxa, “Full Prescribing Information,” 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022512s017lbl.pdf.
  7. Food and Drug Administration, Xarelto: Full Prescribing Information, 2014, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf.
  8. Food and Drug Administration, Eliquis: Full Prescribing Information, 2014, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
  9. E. Nutescu, I. Chuatrisorn, and E. Hellenbart, “Drug and dietary interactions of warfarin and novel oral anticoagulants: an update,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 3, pp. 326–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. A. Leil, C. Frost, X. Wang, M. Pfister, and F. LaCreta, “Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery,” CPT: Pharmacometrics & Systems Pharmacology, vol. 3, p. e136, 2014. View at Google Scholar
  11. K.-H. Liesenfeld, T. Lehr, C. Dansirikul et al., “Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial,” Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2168–2175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, “Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban,” Clinical Pharmacokinetics, vol. 53, no. 1, pp. 1–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Mismetti and S. Laporte, “New oral antithrombotics: a need for laboratory monitoring. For,” Journal of Thrombosis and Haemostasis, vol. 8, no. 4, pp. 621–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H. ten Cate, “Monitoring new oral anticoagulants, managing thrombosis, or both?” Thrombosis & Haemostasis, vol. 107, no. 5, pp. 803–805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Paré, N. Eriksson, T. Lehr et al., “Genetic determinants of dabigatran plasma levels and their relation to bleeding,” Circulation, vol. 127, no. 13, pp. 1404–1412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Reilly, T. Lehr, S. Haertter et al., “The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy),” Journal of the American College of Cardiology, vol. 63, no. 4, pp. 321–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. Food and Drug Administration, Xarelto: Clinical Pharmacology & Biopharmaceutical Review(s), 2009, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf.
  18. Food and drug Administration, “Eliquis: Clinical Pharmacology & Biopharmaceutical Review(s),” 2012, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf.
  19. M. Ehrenschwender, J. Koessler, K. Brunner, and U. Steigerwald, “A 77-year-old man with a prolonged activated partial thromboplastin time,” Clinical Chemistry, vol. 58, no. 10, pp. 1402–1407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Legrand, J. Mateo, A. Aribaud et al., “The use of dabigatran in elderly patients,” Archives of Internal Medicine, vol. 171, no. 14, pp. 1285–1286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. L.-L. Louët, M. Wolf, L. Soufir et al., “Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation,” Thrombosis and Haemostasis, vol. 108, no. 3, pp. 583–585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Schattner, N. Kozak, and J. Friedman, “Fatality in a patient treated with dabigatran,” The American Journal of Emergency Medicine, vol. 31, no. 2, pp. 443.e1–443.e2, 2013. View at Google Scholar · View at Scopus
  23. K. Yokoi, K. Isoda, T. Kimura, and T. Adachi, “Diffuse alveolar hemorrhage associated with dabigatran,” Internal Medicine, vol. 51, no. 18, pp. 2667–2668, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Bounameaux and G. Reber, “New oral antithrombotics: a need for laboratory monitoring. Against,” Journal of Thrombosis and Haemostasis, vol. 8, no. 4, pp. 627–630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Pengo, L. Crippa, A. Falanga et al., “Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results,” Journal of Thrombosis and Haemostasis, vol. 10, no. 10, pp. 1979–1987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Mani and E. Lindhoff-Last, “New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness,” Drug Design, Development and Therapy, vol. 8, pp. 789–798, 2014. View at Google Scholar
  27. A. G. G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas, “Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor,” Thrombosis and Haemostasis, vol. 108, no. 5, pp. 876–886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Huber, K. J. Airaksinen, T. Cuisset, F. Marín, A. Rubboli, and G. Y. H. Lip, “Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe,” Thrombosis & Haemostasis, vol. 106, no. 4, pp. 569–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. D. P. Faxon, J. W. Eikelboom, P. B. Berger et al., “Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective,” Thrombosis and Haemostasis, vol. 106, no. 4, pp. 572–584, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. D. M. Adcock, “Sample integrity and preanalytical variables,” in Quality in Laboratory Hemostasis and Thrombosis, S. O. Kitchen, J. D. Olson, and E. F. Preston, Eds., pp. 45–56, John Wiley & Sons, Blackwell Publishing, 2nd edition, 2013. View at Google Scholar
  31. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno, “Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,” Journal of Thrombosis and Haemostasis, vol. 11, no. 4, pp. 756–760, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.-M. Dogné, “Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate,” Thrombosis and Haemostasis, vol. 107, no. 5, pp. 985–997, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Van Blerk, E. Bailleul, B. Chatelain et al., “Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey,” Thrombosis and Haemostasis, vol. 112, p. 6, 2014. View at Publisher · View at Google Scholar
  34. J. P. Antovic, M. Skeppholm, J. Eintrei et al., “Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma,” European Journal of Clinical Pharmacology, vol. 69, no. 11, pp. 1875–1881, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Douxfils, J.-M. Dogné, F. Mullier et al., “Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate,” Thrombosis and Haemostasis, vol. 110, no. 3, pp. 543–549, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. M. Hawes, A. M. Deal, D. Funk-Adcock et al., “Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels,” Journal of Thrombosis and Haemostasis, vol. 11, no. 8, pp. 1493–1502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Hapgood, J. Butler, E. Malan, S. Chunilal, and H. Tran, “The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples,” Thrombosis and Haemostasis, vol. 110, no. 2, pp. 308–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Lippi, G. L. Salvagno, L. Ippolito, M. Franchini, and E. J. Favaloro, “Shortened activated partial thromboplastin time: causes and management,” Blood Coagulation and Fibrinolysis, vol. 21, no. 5, pp. 459–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. C. S. Kitchens, “To bleed or not to bleed? Is that the question for the PTT?” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2607–2611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. J. W. Eikelboom and J. Hirsh, “Monitoring unfractionated heparin with the aPTT: time for a fresh look,” Thrombosis & Haemostasis, vol. 96, no. 5, pp. 547–552, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Hirsh, T. E. Warkentin, S. G. Shaughnessy et al., “Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety,” Chest, vol. 119, no. 1, pp. 64S–94S, 2001. View at Google Scholar · View at Scopus
  42. W. Mueck, L. C. Borris, O. E. Dahl et al., “Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement,” Thrombosis and Haemostasis, vol. 100, no. 3, pp. 453–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Mueck, B. I. Eriksson, K. A. Bauer et al., “Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery,” Clinical Pharmacokinetics, vol. 47, no. 3, pp. 203–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Tripodi, V. Chantarangkul, C. Guinet, and M. M. Samama, “The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study,” Journal of Thrombosis and Haemostasis, vol. 9, no. 1, pp. 226–228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Baglin, “The role of the laboratory in treatment with new oral anticoagulants,” Journal of Thrombosis and Haemostasis, vol. 11, no. 1, pp. 122–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, “Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay,” Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1263–1271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. M. Samama, J.-L. Martinoli, L. LeFlem et al., “Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor,” Thrombosis and Haemostasis, vol. 103, no. 4, pp. 815–825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Hillarp, F. Baghaei, I. F. Blixter et al., “Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays,” Journal of Thrombosis and Haemostasis, vol. 9, no. 1, pp. 133–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain, and J. M. Dogné, “Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature,” Thrombosis Research, vol. 130, no. 6, pp. 956–966, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Douxfils, A. Tamigniau, B. Chatelain et al., “Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban,” Thrombosis and Haemostasis, vol. 110, no. 4, pp. 723–731, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. J. J. van Veen, J. Smith, S. Kitchen, and M. Makris, “Normal prothrombin time in the presence of therapeutic levels of rivaroxaban,” British Journal of Haematology, vol. 160, no. 6, pp. 859–861, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Rodgers, C. N. Bagot, C. Lawrence, G. Hickman, M. Mcgurk, and R. C. Tait, “Correlating prothrombin time with plasma rivaroxaban level,” British Journal of Haematology, vol. 163, no. 5, pp. 685–687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Harenberg, S. Du, C. Weiss, R. Krämer, D. Hoppensteadt, and J. Walenga, “Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH,” Journal of Thrombosis and Haemostasis, vol. 12, no. 5, pp. 801–804, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. R. C. Becker, J. H. Alexander, L. K. Newby et al., “Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome,” Thrombosis and Haemostasis, vol. 104, no. 5, pp. 976–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Douxfils, C. Chatelain, B. Chatelain, J.-M. Dogné, and F. Mullier, “Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide,” Thrombosis and Haemostasis, vol. 110, no. 2, pp. 283–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Frost, S. Nepal, J. Wang et al., “Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects,” British Journal of Clinical Pharmacology, vol. 76, no. 5, pp. 776–786, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Gouin-Thibault, C. Flaujac, X. Delavenne et al., “Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre french GEHT study,” Thrombosis & Haemostasis, vol. 111, no. 2, pp. 240–248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. G. W. Moore, “Recent guidelines and recommendations for laboratory detection of lupus anticoagulants,” Seminars in Thrombosis and Hemostasis, vol. 40, no. 2, pp. 163–171, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. G. M. A. van Os, B. de Laat, P. W. Kamphuisen, J. C. M. Meijers, and P. G. de Groot, “Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time,” Journal of Thrombosis and Haemostasis, vol. 9, no. 8, pp. 1657–1659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Merriman, Z. Kaplan, J. Butler, E. Malan, E. Gan, and H. Tran, “Rivaroxaban and false positive lupus anticoagulant testing,” Thrombosis and Haemostasis, vol. 105, no. 2, pp. 385–386, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Exner, L. Ellwood, J. Rubie, and A. Barancewicz, “Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study,” Thrombosis and Haemostasis, vol. 109, no. 4, pp. 762–765, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Altman and C. D. Gonzalez, “Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs,” Thrombosis Journal, vol. 12, no. 1, article 7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Stangier and M. Feuring, “Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran,” Blood Coagulation and Fibrinolysis, vol. 23, no. 2, pp. 138–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. R. C. Gosselin, D. M. Dwyre, and W. E. Dager, “Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay,” The Annals of Pharmacotherapy, vol. 47, no. 12, pp. 1635–1640, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Nowak, “The ecarin clotting time, a universal method to quantify direct thrombin inhibitors,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, no. 4, pp. 173–183, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. U. Lange, G. Nowak, and E. Bucha, “Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, no. 4, pp. 184–191, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Douxfils, A. Tamigniau, B. Chatelain, C. Goffinet, J. M. Dogne, and F. Mullier, “Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays,” Thrombosis Journal, vol. 12, article 24, 2014. View at Publisher · View at Google Scholar
  69. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf, “Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects,” European Journal of Clinical Pharmacology, vol. 61, no. 12, pp. 873–880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. M. M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse, “An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma,” Thrombosis and Haemostasis, vol. 104, no. 5, pp. 1078–1079, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. L. M. Asmis, L. Alberio, A. Angelillo-Scherrer et al., “Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories,” Thrombosis Research, vol. 129, no. 4, pp. 492–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. G. T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M. M. Samama, “In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban,” Journal of Thrombosis and Haemostasis, vol. 5, no. 4, pp. 886–888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Harenberg, R. Krämer, C. Giese, S. Marx, C. Weiss, and M. Wehling, “Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability,” Journal of Thrombosis and Thrombolysis, vol. 32, no. 3, pp. 267–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Mani, C. Hesse, G. Stratmann, and E. Lindhoff-Last, “Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time,” Thrombosis and Haemostasis, vol. 106, no. 1, pp. 156–164, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Mani, G. Rohde, G. Stratmann et al., “Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin,” Thrombosis & Haemostasis, vol. 108, no. 1, pp. 191–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. M. M. Samama, G. Contant, T. E. Spiro et al., “Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls,” Thrombosis and Haemostasis, vol. 107, no. 2, pp. 379–387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. S. J. Francart, E. M. Hawes, A. M. Deal et al., “Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels,” Thrombosis and Haemostasis, vol. 111, no. 6, pp. 1133–1140, 2014. View at Publisher · View at Google Scholar
  78. R. C. Becker, H. Yang, Y. Barrett et al., “Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor,” Journal of Thrombosis and Thrombolysis, vol. 32, no. 2, pp. 183–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Harenberg, S. Du, S. Krämer et al., “Novel methods for assessing oral direct factor xa and thrombin inhibitors: use of point-of-care testing and urine samples,” Seminars in Thrombosis and Hemostasis, vol. 39, no. 1, pp. 66–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Harenberg, S. Krämer, S. Du, C. Weiss, and R. Krämer, “Concept of a point of care test to detect new oral anticoagulants in urine samples,” Thrombosis Journal, vol. 11, article 15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Harenberg, S. Kramer, S. Du et al., “Measurement of rivaroxaban and apixaban in serum samples of patients,” European Journal of Clinical Investigation, vol. 44, pp. 743–752, 2014. View at Google Scholar
  82. G. Pernod, P. Albaladejo, A. Godier et al., “Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013,” Archives of Cardiovascular Diseases, vol. 106, no. 6-7, pp. 382–393, 2013. View at Publisher · View at Google Scholar · View at Scopus